About the Company
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CYTK News
Cytokinetics patents new cardiac myosin inhibitors
Cytokinetics Inc. has disclosed cardiac myosin inhibitors reported to be useful for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, ...
Cytokinetics drifts lower as CEO touts standalone strategy
Cytokinetics (CYTK) stock slips after CEO suggests potential for upside without relying solely on a takeover, highlighting ...
Buy Rating Affirmed for Cytokinetics Amid Strong Clinical Progress and Strategic Commercial Preparations
Begin your TipRanks Premium journey today. Cytokinetics (CYTK) Company Description: Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle ...
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn ...
This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag
Hello! This week’s ETF Wrap digs into the jump in biotech funds, as well as an “unusual” trend in U.S. small-cap stocks ...
CYTK Apr 2024 58.000 put
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor ...
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report), Cytokinetics (CYTK – Research Report) and Coherus Biosciences (CHRS – Research ...
Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of ...
100 Stocks You Should Have Invested In 5 Years Ago
If you know even a little bit about finance and investing, then you probably know that the stock market offers the most ...
Q4 2023 CytomX Therapeutics Inc Earnings Call
The pandemic validated the disease-fighting prowess of mRNA vaccines. Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer ...
Ionis stock jumps as MASH drug succeeds in mid-stage trial
Ionis Pharmaceuticals reported positive results from a Phase 2 study of its investigational drug for fatty liver disease.
ALS body takes digital approach to clinical trials access
A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital ...
Loading the latest forecasts...